MicroRNA-26a protects against cardiac hypertrophy via inhibiting GATA4 in rat model and cultured cardiomyocytes

Liu,Yan; Wang,Zhiqian; Xiao,Wenliang

doi:10.3892/mmr.2016.5574

MicroRNA-26a protects against cardiac hypertrophy via inhibiting GATA4 in rat model and cultured cardiomyocytes

Authors:
- Yan Liu
- Zhiqian Wang
- Wenliang Xiao
View Affiliations

Affiliations: Department of Cardiology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: July 28, 2016 https://doi.org/10.3892/mmr.2016.5574
Pages: 2860-2866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pathological cardiac hypertrophy is characterized by deleterious changes developed in cardiovascular diseases, whereas microRNAs (miRNAs) are involved in the mediation of cardiac hypertrophy. To investigate the role of microRNA-26a (miR-26a) in regulating cardiac hypertrophy and its functioning mechanisms, overexpression and suppression of miR‑26a via its mimic and inhibitor in a transverse abdominal aortic constriction (TAAC)-induced rat model and in angiotensin II (Ang II)-induced cardiomyocytes (CMs) was performed. In the rat model, the heart weight (HW) compared with the body weight (BW), the CM area, and expression of the hypertrophy‑associated factors, atrial natriuretic factor (ANF) and β‑myosin heavy chain (β‑MHC), were assessed. In CMs, the protein synthesis rate was determined using a leucine incorporation assay. Mutation of the GATA‑binding protein 4 (GATA4) 3'‑untranslated region (UTR) and overexpression of GATA4 were performed to confirm whether GATA4 is the target of miR‑26a. The results indicated that miR-26a was significantly downregulated in the heart tissue of the rat model, as well as in Ang II‑induced CMs (P<0.05). The TAAC-induced rat model exhibited a higher HW/BW ratio, a larger CM area, and higher expression levels of ANF and β‑MHC. CMs, upon Ang II treatment, also demonstrated a larger CM area, higher levels of ANF and β‑MHC, as well as accelerated protein synthesis. miR‑26a was not able to regulate GATA4 with mutations in the 3'‑UTR, indicating that GATA4 was the direct target of miR‑26a. Overexpression of GATA4 abrogated the inhibitory functions of miR‑26a in cardiac hypertrophy. Taken together, the present study suggested an anti‑hypertrophic role of miR‑26a in cardiac hypertrophy, possibly via inhibition of GATA4. These findings may be useful in terms of facilitating cardiac treatment, with potential therapeutic targets and strategies.

View Figures

View References

1	Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, Roberts R and Marian AJ: Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 97:285–292. 2005. View Article : Google Scholar : PubMed/NCBI
2	Okere IC, Young ME, McElfresh TA, Chess DJ, Sharov VG, Sabbah HN, Hoit BD, Ernsberger P, Chandler MP and Stanley WC: Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling and altered gene expression in hypertension. Hypertension. 48:1116–1123. 2006. View Article : Google Scholar : PubMed/NCBI
3	Doyle B, Sorajja P, Hynes B, Kumar AH, Araoz PA, Stalboerger PG, Miller D, Reed C, Schmeckpeper J, Wang S, et al: Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev. 17:941–951. 2008. View Article : Google Scholar : PubMed/NCBI
4	Weeks KL and McMullen JR: The athlete's heart vs the failing heart: Can signaling explain the two distinct outcomes? Physiology (Bethesda). 26:97–105. 2011. View Article : Google Scholar
5	Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T, Makino S, Manabe T, Murata M and Ogawa S: Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 279:H1635–H1644. 2000.PubMed/NCBI
6	Lezoualc'h F, Metrich M, Hmitou I, Duquesnes N and Morel E: Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol. 44:623–632. 2008. View Article : Google Scholar : PubMed/NCBI
7	Pan J, Singh US, Takahashi T, Oka Y, Palm-Leis A, Herbelin BS and Baker KM: PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol. 202:536–553. 2005. View Article : Google Scholar
8	Yue H, Li W, Desnoyer R and Karnik SS: Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res. 85:90–99. 2010. View Article : Google Scholar
9	Gladka MM, da Costa Martins PA and De Windt LJ: Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol. 52:74–82. 2012. View Article : Google Scholar
10	Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, et al: MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 119:2772–2786. 2009. View Article : Google Scholar :
11	Wang K, Lin ZQ, Long B, Li JH, Zhou J and Li PF: Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem. 287:589–599. 2012. View Article : Google Scholar :
12	Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X and Wang DZ: MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res. 112:1234–1243. 2013. View Article : Google Scholar : PubMed/NCBI
13	Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, et al: MicroRNA-133 controls cardiac hypertrophy. Nat Med. 13:613–618. 2007. View Article : Google Scholar
14	Li Q, Song XW, Zou J, Wang GK, Kremneva E, Li XQ, Zhu N, Sun T, Lappalainen P, Yuan WJ, et al: Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci. 123:2444–2452. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wei L, Yuan M, Zhou R, Bai Q, Zhang W, Zhang M, Huang Y and Shi L: MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a. J Cardiovasc Pharmacol. 65:357–363. 2015. View Article : Google Scholar : PubMed/NCBI
16	Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB and Zhang C: MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol. 170:1831–1840. 2007. View Article : Google Scholar : PubMed/NCBI
17	Sayed D, Hong C, Chen IY, Lypowy J and Abdellatif M: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 100:416–424. 2007. View Article : Google Scholar : PubMed/NCBI
18	Gao J and Liu QG: The role of miR-26 in tumors and normal tissues (Review). Oncol Lett. 2:1019–1023. 2011.
19	Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S and Abdellatif M: GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res. 93:645–654. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhang ZH, Li J, Liu BR, Luo CF, Dong Q, Zhao LN, Zhong Y, Chen WY, Chen MS and Liu SM: MicroRNA-26 was decreased in rat cardiac hypertrophy model and may be a promising therapeutic target. J Cardiovasc Pharmacol. 62:312–319. 2013. View Article : Google Scholar : PubMed/NCBI
21	Parmentier JH, Pavicevic Z and Malik KU: Ang II stimulates phospholipase D through PKCzeta activation in VSMC: Implications in adhesion, spreading and hypertrophy. Am J Physiol Heart Circ Physiol. 290:H46–H54. 2006. View Article : Google Scholar
22	Li R, Xiao J, Qing X, Xing J, Xia Y, Qi J, Liu X, Zhang S, Sheng X, Zhang X and Ji X: Sp1 mediates a therapeutic role of MiR-7a/b in angiotensin II-induced cardiac fibrosis via mechanism involving the TGF-β and MAPKs pathways in cardiac fibroblasts. PLoS One. 10:e01255132015. View Article : Google Scholar
23	Garcia R, Thibault G and Cantin M: Correlation between cardiac hypertrophy and plasma levels of atrial natriuretic factor in non-spontaneous models of hypertension in the rat. Biochem Biophys Res Commun. 145:532–541. 1987. View Article : Google Scholar : PubMed/NCBI
24	Haddad F, Qin AX, Bodell PW, Zhang LY, Guo H, Giger JM and Baldwin KM: Regulation of antisense RNA expression during cardiac MHC gene switching in response to pressure overload. Am J Physiol Heart Circ Physiol. 290:H2351–H2361. 2006. View Article : Google Scholar : PubMed/NCBI
25	Hu X, Li T, Zhang C, Liu Y, Xu M, Wang W, Jia Z, Ma K, Zhang Y and Zhou C: GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model. J Cell Mol Med. 15:1865–1877. 2011. View Article : Google Scholar
26	Charron F, Paradis P, Bronchain O, Nemer G and Nemer M: Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol. 19:4355–4365. 1999. View Article : Google Scholar : PubMed/NCBI
27	Liu YL, Huang CC, Chang CC, Chou CY, Lin SY, Wang IK, Hsieh DJ, Jong GP, Huang CY and Wang CM: Hyperphosphate-induced myocardial hypertrophy through the GATA-4/NFAT-3 signaling pathway is attenuated by ERK inhibitor treatment. Cardiorenal Med. 5:79–88. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xiang F, Sakata Y, Cui L, Youngblood JM, Nakagami H, Liao JK, Liao R and Chin MT: Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol. 290:H1997–H2006. 2006. View Article : Google Scholar : PubMed/NCBI
29	Kwon DH, Eom GH, Kee HJ, Nam YS, Cho YK, Kim DK, Koo JY, Kim HS, Nam KI, Kim KK, et al: Estrogen-related receptor gamma induces cardiac hypertrophy by activating GATA4. J Mol Cell Cardiol. 65:88–97. 2013. View Article : Google Scholar : PubMed/NCBI
30	Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE and Molkentin JD: The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol. 21:7460–7469. 2001. View Article : Google Scholar : PubMed/NCBI